Daniel H. Ahn

6.1k total citations · 1 hit paper
153 papers, 3.7k citations indexed

About

Daniel H. Ahn is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Daniel H. Ahn has authored 153 papers receiving a total of 3.7k indexed citations (citations by other indexed papers that have themselves been cited), including 105 papers in Oncology, 66 papers in Surgery and 40 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Daniel H. Ahn's work include Cholangiocarcinoma and Gallbladder Cancer Studies (48 papers), Pancreatic and Hepatic Oncology Research (45 papers) and Colorectal Cancer Treatments and Studies (41 papers). Daniel H. Ahn is often cited by papers focused on Cholangiocarcinoma and Gallbladder Cancer Studies (48 papers), Pancreatic and Hepatic Oncology Research (45 papers) and Colorectal Cancer Treatments and Studies (41 papers). Daniel H. Ahn collaborates with scholars based in United States, France and United Kingdom. Daniel H. Ahn's co-authors include Tanios Bekaii‐Saab, Glyn Johnson, Stanley Lu, Mitesh J. Borad, Soonmee Cha, Milind Javle, Rachna T. Shroff, Ahmed O. Kaseb, Mohamad Bassam Sonbol and Robert I. Grossman and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Hepatology.

In The Last Decade

Daniel H. Ahn

141 papers receiving 3.7k citations

Hit Papers

Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatm... 2019 2026 2021 2023 2019 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
    2019 321 citations Ramesh K. Ramanathan, Daniel H. Ahn et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Daniel H. Ahn United States 31 2.0k 1.5k 882 803 554 153 3.7k
Jean‐Christophe Sabourin France 31 2.5k 1.2× 737 0.5× 1.0k 1.2× 845 1.1× 453 0.8× 126 4.2k
Satoru Iwasa Japan 30 2.7k 1.4× 1.3k 0.9× 1.9k 2.1× 782 1.0× 478 0.9× 255 4.4k
Chang Ohk Sung South Korea 33 1.8k 0.9× 749 0.5× 838 1.0× 1.4k 1.8× 171 0.3× 142 4.0k
Brian G. Czito United States 32 2.0k 1.0× 1.7k 1.1× 1.4k 1.6× 519 0.6× 524 0.9× 155 3.6k
Guido Lammering Netherlands 40 3.2k 1.6× 1.6k 1.1× 1.3k 1.5× 891 1.1× 1.6k 2.8× 105 4.9k
Takahiro Hasebe Japan 40 2.5k 1.2× 1.1k 0.7× 944 1.1× 1.4k 1.7× 390 0.7× 173 4.8k
Ravit Geva Israel 33 4.1k 2.1× 880 0.6× 1.6k 1.8× 822 1.0× 235 0.4× 134 5.3k
Renata Ferrarotto United States 33 2.7k 1.4× 1.6k 1.1× 975 1.1× 933 1.2× 163 0.3× 210 4.7k
Maximilian Bockhorn Germany 39 2.1k 1.0× 1.3k 0.9× 967 1.1× 1.1k 1.3× 220 0.4× 150 4.0k
Roger Ove United States 11 2.0k 1.0× 1.1k 0.8× 1.7k 2.0× 978 1.2× 492 0.9× 36 4.1k

Countries citing papers authored by Daniel H. Ahn

Since Specialization
Citations

This map shows the geographic impact of Daniel H. Ahn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel H. Ahn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel H. Ahn more than expected).

Fields of papers citing papers by Daniel H. Ahn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel H. Ahn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel H. Ahn. The network helps show where Daniel H. Ahn may publish in the future.

Co-authorship network of co-authors of Daniel H. Ahn

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel H. Ahn. A scholar is included among the top collaborators of Daniel H. Ahn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel H. Ahn. Daniel H. Ahn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ahn, Daniel H., et al.. (2025). Point-of-care ultrasound training among anesthesiology residency programs in the United States. BMC Anesthesiology. 25(1). 105–105.
2.
3.
Naqvi, Syed Arsalan Ahmed, Zhaohui Jin, Harry H. Yoon, et al.. (2025). Efficacy of perioperative and neoadjuvant therapies in gastric and gastroesophageal junction adenocarcinoma: a network meta-analysis. The Oncologist. 30(8). 2 indexed citations
4.
Pai, Reetesh K., Kenneth Lee, Catherine E. Hagen, et al.. (2025). Quantitative Analysis of Rectal Cancer Biopsies With the Digital Pathology Segmentation Algorithm QuantCRC Associates With Therapy Response and Recurrence. Laboratory Investigation. 105(8). 104187–104187.
5.
Ahn, Daniel H., Mitesh J. Borad, Christina Wu, et al.. (2025). Circulating Tumor DNA Testing for Minimal Residual Disease and Its Application in Colorectal Cancer. Cells. 14(3). 161–161. 5 indexed citations
6.
Pai, Rish K., Mitesh J. Borad, Hao Xie, et al.. (2025). Immune Checkpoint Inhibitors for Mismatch Repair–Deficient Gastroesophageal Adenocarcinoma: Outcomes and Feasibility of Nonoperative Management at Mayo Clinic. JCO Precision Oncology. 9(9). e2500492–e2500492.
7.
Ahn, Daniel H., Afsaneh Barzi, Maya Ridinger, et al.. (2024). Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study. Clinical Cancer Research. 30(10). 2039–2047. 20 indexed citations
8.
Ahn, Daniel H., Maya Ridinger, Timothy Lewis Cannon, et al.. (2024). Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS -Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial. Journal of Clinical Oncology. 43(7). 840–851. 11 indexed citations
9.
10.
Desai, Aakash, Daheui Choi, Þorvarður R. Hálfdánarson, et al.. (2024). Molecular Characterization and Therapeutic Opportunities in KRAS Wildtype Pancreatic Ductal Adenocarcinoma. Cancers. 16(10). 1861–1861. 1 indexed citations
11.
McWilliams, Robert R., Pashtoon Murtaza Kasi, Nathan R. Foster, et al.. (2023). Trial in progress: Phase II study of niraparib and dostarlimab for the treatment of germline or somatic homologous recombination repair mutated metastatic pancreatic cancer.. Journal of Clinical Oncology. 41(4_suppl). TPS780–TPS780. 3 indexed citations
12.
Deshmukh, Sachin Kumar, Felipe Batalini, Binbin Zheng-Lin, et al.. (2023). Chemotherapeutic sensitivity in colorectal cancer expressing low RNA of wild type homologous recombination genes.. Journal of Clinical Oncology. 41(16_suppl). 3531–3531. 1 indexed citations
13.
14.
15.
Sonbol, Mohamad Bassam, Daniel H. Ahn, & Tanios Bekaii‐Saab. (2019). Therapeutic Targeting Strategies of Cancer Stem Cells in Gastrointestinal Malignancies. Biomedicines. 7(1). 17–17. 31 indexed citations
16.
Ahn, Daniel H., et al.. (2018). Lambertianic Acid Sensitizes Non-Small Cell Lung Cancers to TRAIL-Induced Apoptosis via Inhibition of XIAP/NF-κB and Activation of Caspases and Death Receptor 4. International Journal of Molecular Sciences. 19(5). 1476–1476. 20 indexed citations
17.
Sonbol, Mohamad Bassam, Belal Firwana, Zhen Wang, et al.. (2017). Second‐line treatment in patients with pancreatic ductal adenocarcinoma: A meta‐analysis. Cancer. 123(23). 4680–4686. 23 indexed citations
18.
Ahn, Daniel H., Kristen K. Ciombor, Sameh Mikhail, & Tanios Bekaii‐Saab. (2016). Genomic diversity of colorectal cancer: Changing landscape and emerging targets. World Journal of Gastroenterology. 22(25). 5668–5668. 11 indexed citations
19.
Farren, Matthew R., Thomas A. Mace, Susan Geyer, et al.. (2015). Systemic Immune Activity Predicts Overall Survival in Treatment-Naïve Patients with Metastatic Pancreatic Cancer. Clinical Cancer Research. 22(10). 2565–2574. 69 indexed citations
20.
Rodić, Nemanja, Jared P. Steranka, Alvin P. Makohon-Moore, et al.. (2015). Retrotransposon insertions in the clonal evolution of pancreatic ductal adenocarcinoma. Nature Medicine. 21(9). 1060–1064. 100 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jean‐Christophe Sabourin Breakdown of academic impact, for papers by Satoru Iwasa Breakdown of academic impact, for papers by Chang Ohk Sung Breakdown of academic impact, for papers by Brian G. Czito Breakdown of academic impact, for papers by Guido Lammering Breakdown of academic impact, for papers by Takahiro Hasebe Breakdown of academic impact, for papers by Ravit Geva Breakdown of academic impact, for papers by Renata Ferrarotto Breakdown of academic impact, for papers by Maximilian Bockhorn Breakdown of academic impact, for papers by Roger Ove
Rankless by CCL
2026